2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow TB-403: new trials by email Literature Review of TB-403 trials Research Report on TB-403
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) THR-317 8mg - Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia | Phase 2 | Completed | ThromboGenics | 8 | 2018-09-18 | 2020-09-02 |
| A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) Ranibizumab 0.5mg, THR-317 8mg, Sham injection - Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Completed | Oxurion | 70 | 2018-04-20 | 2019-08-02 |
| 89Zr-RO5323441 PET Imaging in Glioblastoma Molecular imaging with 89Zr-RO5323441 - Glioblastoma | Phase 2 | Withdrawn | University Medical Center Groningen | 2014-09-01 | 2024-05-06 |
Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Glioblastoma (1) · Idiopathic Juxtafoveal Retinal Telangiectasia (1) · Macular Edema (1) · Retinal Telangiectasis (1)
Oxurion (1) · ThromboGenics (1) · University Medical Center Groningen (1)
France (2) · Switzerland (2) · Belgium (1) · Germany (1) · Netherlands (1) · Slovakia (1) · Spain (1) · United Kingdom (1)
Annemiek M. Walenkamp, MD, PhD (1)
2017 (2)